Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.71 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.71 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398425 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7056008 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL684955 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5405168 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7053112 | 0.88 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7049684 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17278141 | 0.87 | SLC7A5 (0.73) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Hydrochloric Acid SCHEMBL6527457 | 0.85 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL3750512 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL14415641 | 0.84 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| US-5068432-A | Amination and etherification of a halo alcohol and resolution of a racemic mixture | ALDRICH CHEMICAL COMPANY, INC. (US) | 1991-11-26 | — | — | US | claimed |
| WO-2026013142-A3 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS | CONNECTA THERAPEUTICS, S.L. (ES) | 2026-05-07 | — | — | WO | disclosed |
| EP-4678628-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS | Connecta Theapeutics, S.L. (ES) | 2026-01-14 | — | — | EP | disclosed |
| EP-4678628-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS | Connecta Theapeutics, S.L. (ES) | 2026-01-14 | — | — | EP | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-4895845-A | RESERPINE AND TRAZODONE, BUPROPION OR FLUOXETINE ANTIDEPRESSANT | SEED JOHN C (US) | 1990-01-23 | — | — | US | disclosed |
| US-4895845-A | RESERPINE AND TRAZODONE, BUPROPION OR FLUOXETINE ANTIDEPRESSANT | SEED JOHN C (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0336753-A1 | Improvements in or relating to propanamine derivatives | ELI LILLY AND COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4584404-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| US-4313896-A | ANTIDEPRESSANTS, PSYCHOTROPIC AGENTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | SLC6A4 111/4885SLC6A2 171/4885SLC6A3 138/4885 |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | ADORA2A, P2RX5, PNP | SLC6A4 76/4885SLC6A2 102/4885SLC6A3 208/4885 |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HTR2C, HTR5A, HTR2A | SLC6A4 35/4885SLC6A2 94/4885SLC6A3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.